Acquired HIV drug resistance among children and adults receiving antiretroviral therapy in Tanzania: a national representative survey protocol.
HIV & AIDS
internal medicine
microbiology
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
17 12 2021
17 12 2021
Historique:
entrez:
18
12
2021
pubmed:
19
12
2021
medline:
8
3
2022
Statut:
epublish
Résumé
Tanzania is making an enormous effort in scaling-up of antiretroviral therapy (ART). However, people living with HIV (PLHIV) continue to succumb to the challenge of drug resistance. Evidence on drug resistance for a national survey is unavailable in Tanzania. Therefore, we sought to assess viral suppression (vs) rates and magnitude of acquired drug resistance (ADR) among PLHIV. A national survey will be conducted from 26 July to 29 October 2021 in 22 regions, recruiting 2160 participants. These will include adults on ART for 9-15 months and ≥48 months and children on ART for 9-15 months and ≥36 months. A standardised questionnaire will capture participants' demographic and clinical data. Plasma and dried blood spot will be prepared for viral load testing and drug resistance genotyping. Statistical analyses to determine the burden of ADR, characteristics and factors associated therewith will be done using STATA V.15. Ethical approval has been obtained from the National Health Research Ethics Committee of Tanzania (NIMR/HQ/R.8a/Vol.IX/3432). Appropriate participant informed consent or parental consent and assent will be obtained. Dissemination will include a survey report, conference presentations, policy briefs and peer-reviewed publications.
Identifiants
pubmed: 34921085
pii: bmjopen-2021-054021
doi: 10.1136/bmjopen-2021-054021
pmc: PMC8689191
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e054021Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMC Infect Dis. 2019 Mar 12;19(1):246
pubmed: 30871487
Open Forum Infect Dis. 2014 Sep 09;1(2):ofu079
pubmed: 25734147
Infect Dis Rep. 2013 Jun 06;5(Suppl 1):e5
pubmed: 24470969
Trop Med Int Health. 2017 Feb;22(2):221-231
pubmed: 27797443
PLoS One. 2019 Jul 29;14(7):e0220159
pubmed: 31356613
Lancet HIV. 2018 Jul;5(7):e400-e404
pubmed: 29884404
Infect Disord Drug Targets. 2011 Apr;11(2):167-74
pubmed: 21406048
Trop Med Int Health. 2015 Jul;20(7):880-92
pubmed: 25779383
Intervirology. 2012;55(2):98-101
pubmed: 22286876
AIDS Res Ther. 2020 Feb 17;17(1):7
pubmed: 32066473
J Infect Dis. 2013 Jun 15;207 Suppl 2:S49-56
pubmed: 23687289
PLoS One. 2020 Sep 28;15(9):e0232649
pubmed: 32986709
AIDS. 2017 Jan 2;31(1):61-70
pubmed: 27677163
PLoS One. 2015 Jun 17;10(6):e0129210
pubmed: 26083364
BMC Infect Dis. 2020 Oct 19;20(1):773
pubmed: 33076866
HIV AIDS (Auckl). 2021 Feb 25;13:229-237
pubmed: 33664596
J Antimicrob Chemother. 2016 Jun;71(6):1632-6
pubmed: 26888910
AIDS. 2017 Jul 17;31(11):1637-1639
pubmed: 28481772
BMC Infect Dis. 2015 Apr 08;15:175
pubmed: 25886277
AIDS Res Ther. 2020 Jul 10;17(1):39
pubmed: 32650796
BMC Public Health. 2020 Aug 17;20(1):1251
pubmed: 32807138
AIDS Res Ther. 2017 Mar 28;14(1):18
pubmed: 28351430